After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

WSW, NY, July 15th, 2026, FinanceWire

On July 6, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85.00 per share in cash, a total equity value of approximately $10 billion and roughly a 102% premium to Crinetics' undisturbed share price. The prize was Palsonify, a once-daily oral therapy for acromegaly, a rare pituitary disorder that affects an estimated 20,000 diagnosed people in the United States. Vertex called it blockbuster potential.

What made Palsonify valuable was never the biology behind it. Acromegaly already had effective treatments. What Palsonify offered was a format patients would actually use. Entera Bio (NASDAQ: ENTX) is targeting the same opportunity in a disease population roughly ten thousand times larger, with a broader platform behind the lead asset.

The prize was the format, not the molecule

Palsonify, chemical name paltusotine, is a nonpeptide small molecule. So is atumelnant, Crinetics' Phase 3 candidate for congenital adrenal hyperplasia, which Vertex is also acquiring. Crinetics built its platform specifically around small molecules engineered to activate the same hormone receptors that injectable peptide drugs target, without being peptides themselves. It is a legitimate and difficult chemistry problem, and it worked well enough to justify a $10 billion acquisition. But it also looks like a way around the underlying obstacle rather than through it: peptides are hard to deliver orally, so Crinetics designed different molecules that did not need to be.

Every bone-building drug on the market today is an injection

Osteoporosis treatments split into two categories: antiresorptive drugs that slow bone loss, and anabolic drugs that actually rebuild bone and improve our skeleton, typically reserved for higher-risk patients. Every anabolic approved in the United States today, Eli Lilly's Forteo (NYSE: LLY), Paratek's Tymlos, and Amgen's Evenity, is delivered by injection. Forteo and Tymlos are self-administered daily; Evenity is administered by a healthcare provider as two monthly injections, carrying a boxed cardiovascular warning. Evenity alone generated close to $2.1 billion in 2025 sales despite the injection, cost and in-office visit burden, and GlobalData has projected the shift from antiresorptives toward anabolics could add roughly $7 billion in annual sales industry-wide by 2033. No new bone-building drug has been approved for osteoporosis since 2019.

Entera's lead asset, EB613, delivers PTH(1-34), the identical bone-building peptide used in Forteo, which generated approximately $1.6 billion in peak annual sales. Not a mimic. The same peptide, in a once-daily tablet, using Entera's proprietary N-Tab platform to get an intact peptide through the gut wall instead of engineering around the need to. Entera has described EB613 as the first oral anabolic tablet in development for osteoporosis, a category that has had no oral entrant at all. The initial Phase 3 program is in postmenopausal women, where the disease burden is concentrated.

The data held up, and the FDA agreed

A 161-patient, placebo-controlled Phase 2 study, published in the Journal of Bone and Mineral Research, met its primary pharmacodynamic endpoints and secondary bone mineral density endpoints. The trial produced dose-proportional increases in markers of bone formation, reductions in markers of bone resorption, and statistically significant BMD gains at the lumbar spine, total hip, and femoral neck, comparable to published injectable teriparatide data at the same six-month timepoint.

In July 2025, the FDA provided Entera with written alignment, in a Type A meeting response, that a single BMD-based Phase 3 trial could support an NDA for EB613. In December 2025, the FDA extended that framework across the entire field, formally qualifying total hip BMD as a validated surrogate endpoint for all novel osteoporosis drugs. In March 2026, Entera submitted a streamlined 750-patient Phase 3 protocol petitioning for a 12-month BMD endpoint, using the single-tablet formulation intended for commercial launch. On June 22, 2026, the FDA responded with positive feedback on the protocol, supporting Entera’s plan to file a New Drug Application (NDA). Phase 3 initiation is targeted for late 2026, with topline data expected in the second half of 2028.

EB613 is the lead, but the pipeline is bigger

Entera's N-Tab platform is not a one-asset bet. EB612, an oral long-acting PTH tablet for hypoparathyroidism, and EB618, an oral GLP-1/glucagon tablet for obesity and metabolic disease, are both being advanced by the company. A fourth program, an oral GLP-2 tablet for short bowel syndrome, rounds out a four-program pipeline built on the same technology.

BVF Partners, a healthcare-focused investor whose prior positions include ChemoCentryx (acquired by Amgen for approximately $3.7 billion) and Blueprint Medicines (acquired by Sanofi for up to $9.5 billion), and a longstanding position in Protagonist Therapeutics that drew Johnson & Johnson acquisition interest, led a $10 million placement in Entera in April 2026.

While clinical development carries real risk, EB613 delivers the same peptide that has been FDA-approved as an injection since 2002 (Forteo), giving the underlying molecule itself more than two decades of clinical data. The Vertex-Crinetics deal put a fresh, dated number on what a market was prepared to pay for an oral small molecule targeting a peptide to address a real adherence problem, in a disease population a fraction of the size Entera is targeting with EB613. Entera, at a market capitalization of roughly $80 million with an FDA-aligned Phase 3 strategy already in hand and three additional programs behind the lead asset, looks like it is pursuing an even bigger story that is worth watching.

Recent News Highlights from Entera (NASDAQ: ENTX)

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs 

Read this Next >>

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry (NASDAQ: ERNA)

AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug (NYSE: AZN)

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, peer transaction values, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact